EASYHALER IN ASTHMA GUIDELINES
Product info | 01/12/2020
ONE DEVICE AT EVERY STEP OF THE BTS / SIGN
ASTHMA GUIDELINES1
WHEN CONSIDERING THE ENVIRONMENTAL IMPACT OF INHALER DEVICES, BTS / SIGN ADVISES THAT WHERE IT IS CLINICALLY APPROPRIATE TO DO SO1;
| ✔ |
DPIs SHOULD BE PRIORITISED WHERE PATIENTS ARE USING MULTIPLE DEVICE CLASSES AND DISPLAYING POOR INHALER TECHNIQUE. |
| ✔ |
FOR NEW PRESCRIPTIONS, DPIs ARE PRIORITISED. |
| ✔ |
FUTURE AND ADDITIONAL INHALERS WOULD IDEALLY ALSO BE DPIs. |
WITH THE EASYHALER® RANGE, YOU CAN:
- Prescribe a low dose ICS for new patients (aged 6 years and over) with Easyhaler Budesonide (budesonide).2
- Prescribe a range of drug therapies within the Easyhaler® range and have the flexibility to move patients across the BTS / SIGN guidelines to find and maintain the lowest controlling therapy1
- Provide initial add on therapy with Fobumix Easyhaler (budesonide / formoterol fumarate dihydrate) (adults only) and Fusacomb Easyhaler (salmeterol xinafoate / fluticasone dihydrate) (12 years and above)3,4
Download your "Easyhaler and The Guidelines"
|
REFERENCES:
- BTS/SIGN. Position Statement The Environment and Lung Health March 2020. https://www.brit-thoracic.org.uk/document-library/governance-and-policy-documents/positionstatements/environment-and-lung-health-position-statement-2020/
BTS / SIGN = British Thoracic Society / Scottish Intercollegiate Guidelines Network
ICS = Inhaled Corticosteroids, SmPC = Summary of Product Characteristics
DPI = Dry powder inhalers
March 2022 / RESP-330bbf(2)
| Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300. |
Was this article helpful?
Full prescribing information available here
OCTOBER 2023 / RESP-330B(9)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.
